The European Commission on Friday extended the authorization of the Imvanex mpox vaccine to teenagers aged 12 to 17.

With more than 200 mpox-related deaths reported globally, the EMA has approved Imvanex for adolescents aged 12-17 years.

The global vaccine alliance Gavi says it will buy 500,000 doses of vaccine against mpox to fight outbreaks of the disease in ...

The global vaccine group Gavi has ordered 500,000 mpox vaccine doses from the German-Danish company Bavarian Nordic. The UN ...

The EU's drug regulator has approved Bavarian Nordic's mpox vaccine for use in adolescents aged 12 to 17 years, the company ...

LONDON (Reuters) -Bavarian Nordic said on Thursday its mpox vaccine was approved by the EU's drug regulator for use in ...

Congo's South Kivu province is at the epicenter of the world’s latest mpox outbreak, in what the World Health Organization ...

Lessons learned from the COVID pandemic have left the world in a much better position to tackle the current mpox epidemic ...

The World Health Organization says it has granted its first authorization for use of a vaccine against mpox in adults, ...

The World Health Organization and partners on Friday set up a scheme to help bring mpox vaccines, tests and treatments to the ...

The World Health Organization announced Friday it has authorized the use of an mpox vaccine, calling it an “important step” ...

One dose of modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine is moderately effective against mpox infection in at-risk communities.